SCHEMBL829969

SCHEMBL829969

Cn1c(=O)cc(Sc2ccc(Br)cc2)c2cccnc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FEN1 P39748 1/20 0.42
LMNA P02545 3/20 0.40
MAPT P10636 2/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
PDE4A P27815 2/20 0.37
EGFR P00533 1/20 0.37
SRC P12931 1/20 0.37
TNKS O95271 1/20 0.37
KAT2B Q92831 1/20 0.36
TP53 P04637 1/20 0.35
KMT2A Q03164 2/20 0.35
GAA P10253 1/20 0.35
MEN1 O00255 1/20 0.34
ICAM1 P05362 1/20 0.34
SELE P16581 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830438 0.88 HPGD (0.43) FEN1LMNAMAPTHTTSMN1; SMN2
SCHEMBL829817 0.87 FEN1 (0.42) FEN1LMNASMN1; SMN2DDB1CRBN
SCHEMBL830491 0.87 TNKS (0.47) FEN1MAPTHTTSMN1; SMN2NPSR1
SCHEMBL830005 0.87 AHR (0.42) FEN1LMNAMAPTHTTEGFR
SCHEMBL13923062 0.80 FEN1 (0.48) FEN1LMNASMN1; SMN2NPSR1EGFR
SCHEMBL830137 0.78 CYP1A2 (0.45) MAPTSMN1; SMN2PDE4ATP53KMT2A
SCHEMBL834986 0.78 MAPT (0.56) LMNAMAPTHTTSMN1; SMN2NPSR1
SCHEMBL21591678 0.77 FEN1 (0.50) FEN1HTTSMN1; SMN2DDB1CRBN
SCHEMBL25703950 0.72 NQO2 (0.54) FEN1HTTTNKSKMT2A
SCHEMBL835287 0.72 RXFP1 (0.43) LMNAMAPTHTTSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
WO-2008024423-A2 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS XTL BIOPHARMACEUTICALS LTD. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds GTF3C4, HNF4A, TENT4A FEN1 2320/4885LMNA 3725/4885MAPT 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.